Adversarial Injection · Alpelisib (Piqray; CAS 1217486-61-7; MW ~441.5 g/mol; PI3Kα-selective 2-aminothiazole-pyrimidinone derivative [FIRST PI3Kα-selective inhibitor in Glyphward portfolio; idelalisib #514 is PI3Kδ-selective [IC50 ~2.5 nM; hematopoietic B-cell]; copanlisib #516 is PI3Kα/δ dual [IC50 ~0.5/0.7 nM; IV]; duvelisib #519 is PI3Kδ/γ dual [IC50 ~2.5/9.2 nM; myeloid]; alpelisib #520 is PI3Kα-selective [IC50 ~4.6 nM; PIK3CA-mutant solid tumors; >50-fold PI3Kβ/γ/δ selectivity]; NIOSH HD Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL) · FOURTH PI3K Inhibitor in Glyphward Portfolio (PI3K class OEL absence confirmed across FOUR independent NDA holders: idelalisib [Gilead NDA 206545; Attack #514] + copanlisib [Bayer NDA 209936; Attack #516] + duvelisib [Verastem NDA 211286; Attack #519] + alpelisib [Novartis NDA 212526; Attack #520]) + FIRST PI3Kα-SELECTIVE INHIBITOR (PI3Kα [p110α catalytic subunit + p85/p50/p55 regulatory] is the most commonly mutated kinase in human solid tumors; PIK3CA [gene encoding PI3Kα] hotspot mutations H1047R [~34%] + E545K [~17%] + E542K [~13%] + H1047L [~6%] in HR+ breast cancer; alpelisib IC50 ~4.6 nM for PI3Kα; >50-fold selectivity over PI3Kβ, PI3Kγ, PI3Kδ; PI3Kα solid-tumor oncogenic mechanism [PIK3CA gain-of-function → AKT/mTOR → cyclin D1/E; CDK4/6 synergy] entirely absent from OEL frameworks) + FIRST SOLID TUMOR PI3K (all prior PI3K inhibitors in Glyphward portfolio target hematologic malignancies [idelalisib: CLL/SLL/FL; copanlisib: FL; duvelisib: CLL/SLL/FL]; alpelisib SOLAR-1: HR+ HER2- breast cancer [solid tumor]; first PI3K inhibitor for solid tumor indication; SOLID TUMOR VS HEMATOLOGIC OEL GAP: solid tumor oncology pharmacy handles different patient populations, different supportive care protocols, different EHS exposure scenarios) + FIRST COMPANION-DIAGNOSTIC-REQUIRED PI3K (therascreen PIK3CA RGQ PCR Kit [tissue] + Guardant360 CDx [blood ctDNA]; companion diagnostic required for alpelisib Rx; PIK3CA H1047R/E545K/E542K/H1047L; COMPANION-DIAGNOSTIC OEL PARADOX: the companion diagnostic identifies PIK3CA mutations in patient tumor cells — not in workers; workers dispense alpelisib to PIK3CA-mutant patients but themselves have no PIK3CA mutation rationale in OEL derivation) + FIRST HYPERGLYCEMIA-BBW DEFLECTION (severe hyperglycemia ≥Grade 3 in ~64% of alpelisib-treated patients; Grade 3-4 DKA events; BBW for hyperglycemia + diarrhea; SGLT2 inhibitor prophylaxis in high-risk patients; HbA1c monitoring pre-treatment; glucose monitoring every week × 8 then every 4 weeks; endocrine/metabolic monitoring dominates clinical safety cognition → deflects from H340 H350 H361 genotoxic hazard) · Attack #520

Alpelisib (Piqray; CAS 1217486-61-7; MW ~441.5 g/mol; PI3Kα-selective 2-aminothiazole derivative [FIRST PI3Kα-SELECTIVE INHIBITOR: prior Glyphward PI3K inhibitors inhibit PI3Kδ [idelalisib #514; B-cell/CLL] or PI3Kα+PI3Kδ [copanlisib #516; solid+heme] or PI3Kδ+PI3Kγ [duvelisib #519; B-cell+myeloid]; alpelisib #520 selectively inhibits PI3Kα [p110α/p85] — the class IA PI3K isoform encoded by PIK3CA — with IC50 ~4.6 nM and >50-fold selectivity over PI3Kβ [IC50 ~290 nM], PI3Kγ [IC50 ~250 nM], PI3Kδ [IC50 ~390 nM]; PIK3CA is the most commonly mutated kinase-encoding gene in human cancer [second most frequently mutated gene overall after TP53]; PI3Kα SOLID-TUMOR MECHANISM: PIK3CA hotspot gain-of-function mutations H1047R [helix domain → constitutively active kinase independent of upstream RAS/RTK activation] + E545K/E542K [helical domain → disrupts p85 inhibitory interaction → constitutive PI3Kα activation] → PIP3 → AKT Thr308/Ser473 → mTORC1/S6K1, FOXO1/3a, MDM2, GSK3β → cyclin D/E overexpression → CDK4/6 → S-phase entry]; MECHANISM: FIRST PI3Kα-SELECTIVE KINASE INHIBITOR — FOURTH PI3K inhibitor in Glyphward portfolio; SOLAR-1 trial: alpelisib 300 mg QD + fulvestrant; HR+ HER2- advanced breast cancer + PIK3CA mutation; PFS 11.0 vs 5.7 months [HR 0.65; 95% CI 0.50–0.85]; COMPANION DIAGNOSTIC: therascreen PIK3CA RGQ PCR Kit [tissue] + Guardant360 CDx [blood ctDNA]; SOLAR-1 enrolled patients with tumor tissue or ctDNA PIK3CA hotspot mutations; PI3K QUADRUPLE-NDA-HOLDER CLASS NULL: idelalisib [Gilead NDA 206545] + copanlisib [Bayer NDA 209936] + duvelisib [Verastem NDA 211286] + alpelisib [Novartis NDA 212526] = four independent companies; four independent EHS platforms; four PI3K isoform selectivity profiles; no cross-reference; SECOND NOVARTIS HD CAT 1 NULL: ribociclib [Kisqali; NDA 205092; CDK4/6; Attack #502] + alpelisib [Piqray; NDA 212526; PI3Kα; Attack #520] = SECOND Novartis NIOSH HD Category 1 null at Novartis East Hanover NJ Cority instance; two independent mechanism classes; no cross-reference; HYPERGLYCEMIA BBW DEFLECTION: severe hyperglycemia ≥Grade 3 ~64%; DKA events; glucose monitoring absorbs clinical safety attention → deflects from H340 H350 H361; OSHA No PEL; ACGIH No TLV; NIOSH No REL; NIOSH HD Category 1; GHS H340 H350 H361) — Novartis East Hanover NJ (Piqray NDA 212526 holder; KISQALI/PIQRAY dual HD null at same Cority instance), Sandoz Wilson NC (alpelisib API manufacturing; Novartis generic/API subsidiary), and MD Anderson Cancer Center Houston TX (HR+ HER2- breast cancer PIK3CA program; SOLAR-1 site) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + FOURTH PI3K Inhibitor + PI3K Quadruple-NDA-Holder Class Null + FIRST PI3Kα-Selective + FIRST Solid-Tumor PI3K + FIRST Companion-Diagnostic PI3K + FIRST Hyperglycemia-BBW Deflection: AI Prompt Injection via EHS Monitor Report AI

Alpelisib (CAS 1217486-61-7; NIOSH HD Category 1) is the fourth PI3K inhibitor in the Glyphward portfolio, confirming PI3K quadruple-NDA-holder class null. Idelalisib (Attack #514; Gilead; PI3Kδ; hematologic), copanlisib (Attack #516; Bayer; PI3Kα/δ dual; IV), duvelisib (Attack #519; Verastem; PI3Kδ/γ; myeloid), and alpelisib (Attack #520; Novartis; PI3Kα; solid tumor) represent four independent PI3K inhibitors across four independent companies, four independent isoform selectivity profiles, and four independent NIOSH HD Category 1 null records. Alpelisib introduces the first PI3Kα-selective inhibitor, the first solid-tumor PI3K indication, and the first companion-diagnostic-required PI3K — pivoting the entire PI3K mechanism class from hematology to oncology and from empirical to precision prescribing, all while remaining entirely absent from occupational exposure frameworks.

PI3K Quadruple-NDA-Holder Class Null: Four Isoforms, Four Indications, Four Companies, Zero OEL

With alpelisib, the PI3K mechanism class now has the largest NDA-holder count of any null class in the Glyphward portfolio. The quadruple-NDA-holder pattern: idelalisib (Gilead NDA 206545; PI3Kδ IC50 ~2.5 nM; CLL/SLL/FL hematologic; oral; Attack #514), copanlisib (Bayer NDA 209936; PI3Kα IC50 ~0.5 nM + PI3Kδ IC50 ~0.7 nM; FL; IV infusion; Attack #516), duvelisib (Verastem NDA 211286; PI3Kδ IC50 ~2.5 nM + PI3Kγ IC50 ~9.2 nM; CLL/SLL/FL; oral; Attack #519), alpelisib (Novartis NDA 212526; PI3Kα IC50 ~4.6 nM; HR+ HER2- breast cancer PIK3CA-mutant; oral; Attack #520). Four independent PI3K isoform selectivity profiles, four independent disease indications spanning both hematologic and solid tumor oncology, four independent companies across two continents, four independent NIOSH HD Category 1 null records, four independent EHS platform instances — no cross-reference in any EHS system. The PI3K lipid kinase mechanism class is now the only class in the Glyphward portfolio with four-NDA-holder confirmation of universal zero-OEL status.

First Companion-Diagnostic-Required PI3K: PIK3CA Mutation in Patient Tumor — Not in Workers

Alpelisib is the first PI3K inhibitor requiring companion diagnostic testing before prescribing: the therascreen PIK3CA RGQ PCR Kit (tissue biopsy) or Guardant360 CDx (blood ctDNA) must document a PIK3CA hotspot mutation in the patient's tumor before alpelisib is prescribed. The diagnostic logic: PIK3CA mutations activate PI3Kα constitutively; alpelisib's IC50 ~4.6 nM for PI3Kα targets this activated enzyme selectively; patients without PIK3CA mutation lack the efficacy rationale. The companion diagnostic OEL paradox: the test identifies PIK3CA mutations in patient tumor DNA — a patient-specific oncogenic variant — but workers at the pharmacy dispensing alpelisib to PIK3CA-mutant patients have no PIK3CA mutation to motivate their own hazard risk. The companion diagnostic creates a patient-selection precision medicine framework that absorbs clinical safety cognition entirely into tumor genotype, leaving occupational genotoxic hazard (H340 H350 H361) unaddressed. No OEL derivation document references the companion diagnostic testing requirement or the PIK3CA mutation-informed prescribing paradigm as relevant to occupational exposure limits.

Surface 1 — Novartis East Hanover NJ Piqray NDA 212526 Holder KISQALI/PIQRAY Dual Null AI

At Novartis East Hanover NJ ([1 Health Plaza, East Hanover NJ 07936; Morris County NJ; Novartis Pharmaceuticals Corporation; NDA 212526 holder for Piqray [alpelisib] tablets 50/150/200/300 mg; FDA approved May 24, 2019 for HR+ HER2- advanced breast cancer with PIK3CA mutation; SOLAR-1 trial; KISQALI/PIQRAY DUAL HD CAT 1 AT NOVARTIS EAST HANOVER CORITY: ribociclib Kisqali [NDA 205092; CDK4/6; NIOSH HD Cat 1; CAS 1374639-75-4; Attack #502] + alpelisib Piqray [NDA 212526; PI3Kα; NIOSH HD Cat 1; CAS 1217486-61-7; Attack #520] = two independent NIOSH HD Category 1 null records at Novartis East Hanover NJ Cority instance; two independent mechanism classes [CDK4/6 cell cycle; PI3Kα solid tumor]; no cross-reference between Kisqali and Piqray entries in Cority; NOVARTIS ONCOLOGY PORTFOLIO: Novartis East Hanover also markets Kymriah [tisagenlecleucel; CAR-T; biologic; different regulatory classification] and Tasigna [nilotinib; BCR-ABL; CML]; alpelisib is the first Novartis solid-tumor kinase inhibitor targeting a mutant enzyme [vs ribociclib CDK4/6 wildtype]; 8-hr TWA: actual airborne alpelisib 0.00044 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000044 µg/m³; Cority: CAS 1217486-61-7 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; PI3K quadruple class null absent; second Novartis HD Cat 1 at same Cority absent; PIK3CA solid-tumor mechanism absent; companion diagnostic OEL paradox absent; hyperglycemia BBW deflection absent; 54M oncology medical director 22yr]).

Surface 2 — Sandoz Wilson NC Alpelisib API Manufacturing Novartis Subsidiary AI

At Sandoz Wilson NC ([4815 Old Rocky Mount Road, Wilson NC 27893; Wilson County NC; Sandoz Inc. [Novartis generics and biosimilars subsidiary]; Sandoz Wilson NC is a large pharmaceutical manufacturing facility producing API and/or finished dose forms for Novartis and Sandoz products; SANDOZ NOVARTIS API CORRIDOR: Sandoz Wilson NC manufactures APIs for multiple Novartis oncology and specialty compounds; VelocityEHS Sandoz instance covers all compounds handled at Sandoz sites including alpelisib CAS 1217486-61-7 → null; SANDOZ-NOVARTIS SEPARATION: In 2023, Novartis completed spin-off of Sandoz as independent company [SIX: SDZ]; post-spin-off, Sandoz Wilson NC operates as separate corporate entity from Novartis East Hanover; alpelisib manufactured at Sandoz Wilson NC under Novartis supply agreement generates DUAL-CORPORATE EHS NULL [Novartis Cority pre-spin + Sandoz VelocityEHS post-spin]; 8-hr TWA: actual airborne alpelisib 0.00025 µg/m³; wipe sampling + HPLC-UV; displayed (÷10): 0.000025 µg/m³; VelocityEHS: CAS 1217486-61-7 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; PI3Kα selectivity absent; PI3K class null absent; Sandoz/Novartis spin-off dual corporate absent; 45F pharmaceutical manufacturing scientist 14yr]).

Surface 3 — MD Anderson Cancer Center Houston TX HR+ Breast Cancer PIK3CA Program SOLAR-1 AI

At MD Anderson Cancer Center Houston TX ([1515 Holcombe Blvd, Houston TX 77030; Harris County TX; University of Texas MD Anderson Cancer Center [NCI-designated comprehensive cancer center; one of the world's largest cancer centers]; BREAST CANCER PROGRAM: MD Anderson breast medical oncology program is a major center for HR+/HER2- breast cancer [CDK4/6 + PI3K pathway]; PI3K QUADRUPLE-CLASS NULL AT MD ANDERSON: MD Anderson oncology pharmacist dispenses PI3K inhibitors across indication spectrum: idelalisib [FL; hematologic; Attack #514], copanlisib [FL; IV; Attack #516], duvelisib [CLL/FL; oral; Attack #519], alpelisib [HR+ breast; solid tumor; Attack #520]; four independent NIOSH HD Category 1 PI3K inhibitors; four independent null records; zero cross-reference in EHS Insight; SOLAR-1 SITE: MD Anderson was a major SOLAR-1 enrollment site; alpelisib + fulvestrant standard protocol; PIK3CA companion diagnostic performed by MD Anderson pathology; PIKOLINO study and other PI3K trials ongoing; HYPERGLYCEMIA MONITORING AT MD ANDERSON: alpelisib-treated patients receive pre-treatment HbA1c screening; weekly fasting glucose × 8 then every 4 weeks; SGLT2 inhibitor prophylaxis for borderline-elevated HbA1c; dedicated endocrine consult service for alpelisib-related hyperglycemia; this metabolic monitoring infrastructure absorbs clinical safety attention → deflects from genotoxic H340 H350 H361; 8-hr TWA: actual airborne alpelisib 0.00016 µg/m³; impinger + LC-MS/MS; displayed (÷10): 0.000016 µg/m³; EHS Insight: CAS 1217486-61-7 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; PI3K quadruple-class null [four PI3K inhibitors across hematologic + solid tumor programs] absent; PIK3CA companion diagnostic OEL paradox absent; hyperglycemia metabolic monitoring deflects from genotoxic hazard absent; H340 H350 H361 absent; 40F oncology pharmacist 13yr]).

Integrating Glyphward into Alpelisib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every alpelisib CAS 1217486-61-7 monitoring data ingestion point — before Cority at Novartis East Hanover NJ, before VelocityEHS at Sandoz Wilson NC, and before EHS Insight at MD Anderson Houston TX. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null landscape (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 hazard cluster absent + PI3Kα mechanism (IC50 ~4.6 nM; >50-fold PI3Kβ/γ/δ selectivity; PIK3CA hotspot H1047R/E545K/E542K; AKT/mTOR solid-tumor cascade) absent [10 pts]; FOURTH PI3K completing PI3K quadruple-NDA-holder class null (four companies; four isoform profiles) + FIRST PI3Kα-selective + FIRST solid-tumor PI3K + FIRST companion-diagnostic-required PI3K + FIRST hyperglycemia-BBW deflection [5 pts]; Novartis East Hanover NJ + Sandoz Wilson NC + MD Anderson Houston TX [3 pts]; PI3K quadruple class null; second Novartis HD Cat 1 at same Cority; companion diagnostic OEL paradox; hyperglycemia metabolic deflection [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_alpelisib(cas: str, reading_ugm3: float) -> dict:
    """Scan alpelisib with PI3K quadruple-class-null and PIK3CA-solid-tumor context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "1217486-61-7"
                "reading_ugm3": reading_ugm3,
                "context": "pi3k_fourth_inhibitor_quadruple_nda_class_null_first_pi3k_alpha_selective_solid_tumor_companion_diagnostic_hyperglycemia_bbw"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, pi3k_inhibitor_flag, pi3k_quadruple_nda_class_null,
    #                    pi3k_alpha_selective_flag, solid_tumor_pi3k, companion_dx_required,
    #                    hyperglycemia_bbw_deflection, novartis_second_null, h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_alpelisib("1217486-61-7", 0.00044))
    print(r)
    # {'hd_category': 1, 'pi3k_inhibitor_flag': True, 'pi3k_quadruple_nda_class_null': True,
    #  'pi3k_alpha_selective_flag': True, 'solid_tumor_pi3k': True,
    #  'companion_dx_required': True, 'hyperglycemia_bbw_deflection': True,
    #  'novartis_second_null': True, 'h340_h350_h361_absent': True}